

Supplementary Tables 1–5: Physician-centered outcomes.

Table 1. Degree of arthritis activity at Week 0 and Week 12.

	40 mg (n = 49)		80 mg (n = 48)	
Arthritis activity	Week 0	Week 12	Week 0	Week 12
- none; N (%)	0 (0%)	24 (59%)	0 (0%)	26 (63%)
- mild; N (%)	10 (20%)	11 (27%)	11 (23%)	10 (24%)
- moderate; N (%)	21 (43%)	5 (12%)	21 (44%)	3 (7%)
- active; N (%)	14 (29%)	1 (2%)	15 (31%)	1 (2%)
- very active; N (%)	4 (8%)	0 (0%)	1 (2%)	1 (2%)
Missing data; N		8		7

Table 2. Presence of swelling at Week 0 and Week 12.

	40 mg (n = 49)		80 mg (n = 48)	
Swelling	Week 0	Week 12	Week 0	Week 12
- present; N (%)	48 (98%)	15 (37%)	42 (88%)	13 (32%)
- absent; N (%)	1 (2%)	26 (63%)	6 (13%)	28 (68%)
Missing data; N		8		7

Table 3. Presence of functional limitation at Week 0 and Week 12.

	40 mg (n = 49)		80 mg (n = 48)	
Functional limitation	Week 0	Week 12	Week 0	Week 12
- present; N (%)	13 (29%)	5 (12%)	7 (15%)	6 (15%)
- absent; N (%)	32 (71%)	36 (88%)	39 (85%)	35 (85%)
Missing data; N	4	8	2	7

Table 4. Change of swelling from Week 0 through Week 12; N (%).

	40 mg (n = 49)		80 mg (n = 48)	
Week 0: swelling present				
- improvement ¹	25 (63%)		24 (67%)	
- no change	15 (38%)		12 (33%)	
Week 0: swelling absent				
- no change	1 (100%)		4 (80%)	
- worsening ²	0 (0%)		1 (20%)	
Missing data; N	8		7	

¹ Absence of swelling at Week 12

² Presence of swelling at Week 12

Table 5. Change of functional limitation from Week 0 through Week 12; N (%).

	40 mg (n = 49)		80 mg (n = 48)	
Week 0: extension limitation present				
- improvement ¹	7 (70%)		3 (60%)	
- no change	3 (30%)		2 (40%)	
Week 0: extension limitation absent				
- no change	26 (93%)		30 (88%)	
- worsening ²	2 (7%)		4 (12%)	
Missing data; N	11		9	

¹ Absence of functional limitation at Week 12

² Presence of functional limitation at Week 12